Synthetic Inhibitors of Nucleoside Monophosphate-Kinases

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: 25 September 2024 | Viewed by 1107

Special Issue Editors


E-Mail
Guest Editor
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400012 Cluj-Napoca, Romania
Interests: adenylate kinase; enzymatic inhibitors; antibiotic resistance; natural products

E-Mail Website
Guest Editor
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Medicine and Pharmacy “Iuliu Hatieganu”, 400012 Cluj-Napoca, Romania
Interests: antibiotics discovery; anticancerous drugs discovery; medicinal chemistry; organic synthesis
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Iuliu Hațieganu University of Medicine and Pharmacy, 41 Victor Babeș Street, 400012 Cluj Napoca, Romania
Interests: computational chemistry; drug discovery; medicinal chemistry
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The scope of the new Special issue on the inhibitors of nucleoside monophosphate-kinases (NMP kinases) (EC 2.7.4.4) is motivated by the key role of NMP kinases in metabolism, cell division and other essential cellular functions. These kinases are essential enzymes that catalyse the reversible phosphorylation of nucleoside monophospates in nucleoside diphospates. ATP is the most efficient phosphate donor. The NMP kinases involved in purine metabolism are the adenylate kinase (AMP kinase) and guanilate kinase (GMP kinase); those involved in pyrimidinic metabolism are tymidilate kinase (TMP kinase), urydilate kinase (UMP kinase), and cytidilate kinase (CMP kinase); and for eucaryotes, there is the bi-functional enzyme UMP/CMP kinase. Biochemical and crystallographic studies characterize the catalytic and structural properties of many NMP kinases. The structural and catalytic differences between  bacterial NMP kinases and their eukaryotic counterparts allows advancing studies on the inhibitors of these enzymes. Mutagenesis studies greatly advance the understanding of the regulation of NMP kinases by different ligands. Principally, we are interested in the connection of human adenylate kinases and their mutants with pathological conditions. There are nine isoenzymes and several subforms of adenylate kinases described in eukaryotes that differ from their bacterial counterparts. The adenylate kinases and other NMP kinases can be viable targets for new synthetic or natural compounds.

We welcome research articles and reviews that advance the knowledge about the field of inhibitors of NMP kinases.

Dr. Mihaela Ileana Ionescu
Prof. Dr. Ovidiu Oniga
Dr. Cristina Nastasă
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nucleoside monophosphate-kinases
  • adenylate kinase
  • urydilate kinase
  • tymidilate kinase
  • guanilate kinase
  • cytidilate kinase
  • natural inhibitors
  • enzymatic activity
  • drug design
  • structural studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

10 pages, 1425 KiB  
Review
Trackins (Trk-Targeting Drugs): A Novel Therapy for Different Diseases
by George N. Chaldakov, Luigi Aloe, Stanislav G. Yanev, Marco Fiore, Anton B. Tonchev, Manlio Vinciguerra, Nikolai T. Evtimov, Peter Ghenev and Krikor Dikranian
Pharmaceuticals 2024, 17(7), 961; https://doi.org/10.3390/ph17070961 - 19 Jul 2024
Viewed by 793
Abstract
Many routes may lead to the transition from a healthy to a diseased phenotype. However, there are not so many routes to travel in the opposite direction; that is, therapy for different diseases. The following pressing question thus remains: what are the pathogenic [...] Read more.
Many routes may lead to the transition from a healthy to a diseased phenotype. However, there are not so many routes to travel in the opposite direction; that is, therapy for different diseases. The following pressing question thus remains: what are the pathogenic routes and how can be they counteracted for therapeutic purposes? Human cells contain >500 protein kinases and nearly 200 protein phosphatases, acting on thousands of proteins, including cell growth factors. We herein discuss neurotrophins with pathogenic or metabotrophic abilities, particularly brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), pro-NGF, neurotrophin-3 (NT-3), and their receptor Trk (tyrosine receptor kinase; pronounced “track”). Indeed, we introduced the word trackins, standing for Trk-targeting drugs, that play an agonistic or antagonistic role in the function of TrkBBDNF, TrkCNT−3, TrkANGF, and TrkApro-NGF receptors. Based on our own published results, supported by those of other authors, we aim to update and enlarge our trackins concept, focusing on (1) agonistic trackins as possible drugs for (1a) neurotrophin-deficiency cardiometabolic disorders (hypertension, atherosclerosis, type 2 diabetes mellitus, metabolic syndrome, obesity, diabetic erectile dysfunction and atrial fibrillation) and (1b) neurodegenerative diseases (Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis), and (2) antagonistic trackins, particularly TrkANGF inhibitors for prostate and breast cancer, pain, and arrhythmogenic right-ventricular dysplasia. Altogether, the druggability of TrkANGF, TrkApro-NGF, TrkBBDNF, and TrkCNT−3 receptors via trackins requires a further translational pursuit. This could provide rewards for our patients. Full article
(This article belongs to the Special Issue Synthetic Inhibitors of Nucleoside Monophosphate-Kinases)
Show Figures

Figure 1

Back to TopTop